Diligence memo · auto-generated · as of July 3, 2026
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Castle Creek Biosciences, Inc. operates in Biotechnology, based in Exton. Dedicated to making life better for people suffering from rare diseases with few or no treatment options
Sub-sector tags: biotech.
Capital & rounds (filed)filed
Castle Creek Biosciences, Inc. has raised $840M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $561M on 2018-10-09.
Most recent recorded round closed around 2025-02-24.
Valuation (modeled)modeled
Provath models Castle Creek Biosciences, Inc. at approximately $805M (range $468M–$974M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.28× the median modeled value of Growth/Late Biotechnology companies in 2025–2027 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Neuralink Corp., Eikon Therapeutics, Inc., Grail, Inc., Treeline Biosciences, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.